Surgeons completed radical prostatectomy using new-generation robot
Cleveland Clinic is the first hospital in the country to successfully perform surgeries using the Single Port SP Robot, which inserts all surgical instruments through one small abdominal incision, improving surgical outcomes and allowing quicker patient recovery.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
On Sept. 28, Cleveland Clinic surgeons used the SP Robot to perform three surgeries — two surgeries to remove cancerous prostates and one surgery to remove an enlarged prostate blocking the urinary system through the bladder.
Jihad Kaouk, MD, Director of the Center for Robotic and Image Guided Surgery in the Glickman Urologic and Kidney Institute, was the first to perform and publish on robotic single-port surgery in 2008 using standard robotic systems and coining the phrase R-LESS (robotic laparoendoscopic single site surgery).
After completing and publishing the first ever clinical use for the SP robot in Europe, Dr. Kaouk and his team also performed last week’s radical prostatectomies and transvesical simple prostatectomy at Cleveland Clinic. The new purpose-built robotic SP system will allow the single port approach to be more feasible.
“We anticipate that this new generation of robots will allow for new and different routes of surgeries that haven’t previously been possible,” Dr. Kaouk says. “For example, we can now go through a patient’s perineum instead of their belly to perform prostate surgery and avoid touching the bowel, or work through the retroperitoneal space to perform kidney surgery without entering the abdomen, allowing for quicker recovery time.”
Currently, the SP Robot is only FDA-approved for urologic surgeries, with plans to expand to ENT and colorectal surgeries in the near future.
“We are proud to offer this surgical approach and be on the forefront of surgical innovation,” adds Mark A. Taylor, MD, Chairman of Surgical Operations at Cleveland Clinic.
Advertisement
Dr. Kaouk worked with the Intuitive Inc. team of engineers to test and improve the new robotic system. Dr. Kaouk is a paid consultant, speaker or member of the advisory committee for Endocare, Inc. and Intuitive Surgical, Inc.
Advertisement
Advertisement
Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population
Care paths and research initiatives aim to answer unmet clinical needs
Study shows high rate of hematologic responses, low rate of disease progression
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour